Tadocizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Tadocizumab
Monoclonal antibody
TypeFab fragment
SourceHumanized (from mouse)
TargetIntegrin αIIbβ3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC2107H3252N562O673S12
Molar mass47609.17 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.[1] It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets. [2] The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.[1]

References[edit]

  1. ^ a b Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.
  2. ^ Lodish H, Berk A, Matsudaira P, Kaiser CA, Krieger M, Scott MP, Zipursky L, Darnell J (2003). Molecular cell biology (5th ed.). New York: W.H. Freeman. p. 973. ISBN 978-0-7167-4366-8.